Clinical prognostic factors in patients with recurrent or metastatic carcinoma of the head and neck treated with immune checkpoints therapies.

Carlo Resteghini,Stefano Cavalieri,Alessandro Rametta,Salvatore Alfieri,Donata Galbiati,Francesca Platini,Laura D. Locati,Paolo Bossi,Cristiana Bergamini,Roberta Granata,Ester Orlandi,Cesare Piazza,Moela Mancinelli,Lisa Licitra

Clinical prognostic factors in patients with recurrent or metastatic carcinoma of the head and neck treated with immune checkpoints therapies.

2019

Carlo Resteghini
Stefano Cavalieri
Alessandro Rametta
Salvatore Alfieri
Donata Galbiati
Francesca Platini
Laura D. Locati
Paolo Bossi
Cristiana Bergamini
Roberta Granata
Ester Orlandi
Cesare Piazza
Moela Mancinelli
Lisa Licitra

e17530Background: Immunotherapy (IT) provides advantages in a small proportion of recurrent / metastatic head and neck squamous cell carcinoma (RM HNSCC) patients (pts). Predictive biomarkers are s...

Keywords:

Metastatic carcinoma
Immune system
Pathology
Oncology
Internal medicine
Medicine
Immunotherapy
in patient
predictive biomarker
Head and neck squamous-cell carcinoma
head and neck

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations